Yixin Pfister-Fu
We have observed 12 EP applications Yixin Pfister-Fu has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after August 17, 2014). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:
NEW FORMS AND SALTS OF A DIHYDROPYRROLO[1,2-C]IMIDAZOLYL ALDOSTERONE SYNTHASE OR AROMATASE INHIBITOR
- IPC classification:
- A61K 31/407, C07D 487/04, A61P 5/38
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ NO OPPOSITION FILED WITHIN TIMELIMIT
FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS
- IPC classification:
- A61K 31/506, A61P 19/08
- Applicant:
- Novartis AG
- Agent:
- Jennifer Lucy Harris, Kilburn & Strode LLP
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ The patent has been granted
TYROSINE KINASE INHIBITOR COMBINATIONS AND THEIR USE
- IPC classification:
- A61K 45/06, A61K 31/53, A61K 31/506, A61K 31/5025
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ GRANT OF PATENT INTENDED
COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS
- IPC classification:
- A61K 38/31, A61K 31/4164, A61P 5/00
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ EXAMINATION IN PROGRESS
Antibody formulations
- IPC classification:
- A61K 39/395, A61K 9/00, C07K 16/28, C07K 16/00
- Applicant:
- Novartis AG
- Applicant:
- GlaxoSmithKline LLC
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Agent:
- Alastair George Sayce, GlaxoSmithKline
- Status:
- █ The patent has been granted
PRESSURE RESPONSIVE DOWNHOLE TOOL HAVING A SELECTIVELY ACTIVATABLE PRESSURE RELIEF VALVE AND RELATED METHODS
- IPC classification:
- E21B 34/08, E21B 34/06
- Applicant:
- Halliburton Energy Services, Inc.
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Agent:
- Hoffmann Eitle PartmbB
- Status:
- █ GRANT OF PATENT INTENDED
NOVEL PHARMACEUTICAL COMPOSITION
- IPC classification:
- A61K 31/519, A61K 9/14, A61P 35/00
- Applicant:
- Novartis AG
- Applicant:
- GlaxoSmithKline LLC
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ EXAMINATION REQUESTED
COMBINATION
- IPC classification:
- A61K 9/20, C07D 231/38, A61P 35/00
- Applicant:
- GlaxoSmithKline LLC
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ GRANT OF PATENT INTENDED
COMBINATION THERAPY CONTAINING A PI3K-ALPHA INHIBITOR AND FGFR KINASE INHIBITOR FOR TREATING CANCER
- IPC classification:
- A61P 35/00, A61K 31/506, A61K 31/4439, A61K 45/06
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ APPLICATION WITHDRAWN
PHARMACEUTICAL DOSAGE FORMS
- IPC classification:
- A61K 31/506, A61K 9/48, A61K 9/16
- Applicant:
- Novartis AG
- Agent:
- Jennifer Lucy Harris, Kilburn & Strode LLP
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ EXAMINATION REQUESTED
COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER
- IPC classification:
- C07K 16/28, C07K 16/24, A61K 39/395
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ Request for examination was made
USE OF THE IL-1BETA BINDING ANTIBODY CANAKINUMAB FOR TREATING OR ALLEVATING SYMPTOMS OF PULMONARY SARCOIDOSIS
- IPC classification:
- A61K 39/00, A61P 11/00
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ Request for examination was made